We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > MammaPrint

News List

MammaPrint® Becomes Only Molecular Diagnostic Recommended for Early-Stage Node-Positive Breast Cancer Patients in ASCO-Endorsed Cancer Care b3cnewswire
June 27, 2019
MammaPrint® Becomes Only Molecular Diagnostic Recommended for Early-Stage Node-Positive Breast Cancer Patients in ASCO-Endorsed Cancer Care Ontario Guidelines.
Agendia Announces Publication of Study Validating Use of MammaPrint and BluePrint Molecular Diagnostics using Targeted RNA Next-Generation Sequencing Technology b3cnewswire
June 21, 2019
Agendia Announces Publication of Study Validating Use of MammaPrint and BluePrint Molecular Diagnostics using Targeted RNA Next-Generation Sequencing Technology.
Agendia Announces CE Mark for NGS-Based MammaPrint® BluePrint® Kit Enhancing Access to Personalized b3cnewswire
March 22, 2018
Agendia, Inc., today announces that its next-generation sequencing -based MammaPrint® BluePrint® Breast Cancer Recurrence and Molecular Subtyping Kit is now CE marked, enabling the Company to commercialize the device in Europe.